Loading
companiesCompany
Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)
The Indian company whose trispecific antibody ISB 2001 for multiple myeloma was licensed to AbbVie in 2025 for 700 million dollars upfront, the largest deal for an Indian-discovered cancer drug.
Overview
Glenmark was founded on 18 November 1977 by Gracias Saldanha in Mumbai. In January 2024 it consolidated oncology discovery into Ichnos Glenmark Innovation (IGI), a venture with its subsidiary Ichnos Sciences, with three molecules in the clinic at launch. In July 2025 IGI licensed ISB 2001, a BCMA x CD38 x CD3 trispecific T-cell engager in phase 1 for relapsed or refractory multiple myeloma, to AbbVie for 700 million dollars upfront and up to 1.225 billion dollars in milestones plus royalties; AbbVie took North America, Europe, Japan and Greater China and Glenmark kept India and emerging markets. In 2025 Glenmark also in-licensed the HER2 ADC trastuzumab rezetecan from Hengrui (a deal valued at up to 1.1 billion dollars) and the EGFR inhibitor aumolertinib from Hansoh for several regions.
Headquarters
Mumbai, IN
Scorecard
All companies#172of 1244 companies, score 33
- approved products +6
- phase 1/2 +1
- targets +6
- modalities +4
- regions +1
- 24-month regulatory events +2
- registry trials +13
1 approved, 0 in phase 3, 1 earlier, 3 targets, 40 registry studies. Formula on the scorecards page.
Type
Large pharma · GLENMARK.NS
Stage
Public
Website
Founded
1977
Phase 1Trispecific T-cell engager (BCMA x CD38 x CD3)
An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug.
ApprovedADC
Hengrui's HER2 ADC, approved in China for lung cancer and showing Enhertu-scale results in breast cancer, part of a wave of Chinese ADCs heading for global trials.
Similar pages
- PersonAjai Chari
Shares CD38, Bispecific antibodies, T-cell engagers (bispecific), Multiple myeloma.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Antibody-drug conjugate (ADC).
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Antibody-drug conjugate (ADC).
- TechnologyTrispecific antibodies
Shares Bispecific antibodies, T-cell engagers (bispecific), Multiple myeloma.
- PersonPhilippe Moreau
Shares CD38, BCMA, Bispecific antibodies, T-cell engagers (bispecific).
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares ISB 2001, Multiple myeloma.
- TrialA Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Antibody-drug conjugate (ADC).
- IdeaAn open engineering platform for academic ADCs and bispecifics
Shares The valley of death between lab and product, Bispecific antibodies, T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
cancers
fronts
technologies
targets
drugs
Phase 1Trispecific T-cell engager (BCMA x CD38 x CD3)
ApprovedADC